The healthcare costs of treating human papillomavirus-related cancers in Norway

[1] Forman D(2012)Global burden of human papillomavirus and related diseases Vaccine 30 F12-F23

[2] de Martel C(2014)Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials Lancet 383 524-532

[3] Lacey CJ(2012)Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway Br J Cancer 106 1571-71

[4] Soerjomataram I(2015)Kostnader ved masseundersøkelsen mot livmorhalskreft Sykeplein Forskning 10 62-147

[5] Lortet-Tieulent J(2014)Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys PLoS ONE 9 e89974-2201

[6] Bruni L(2012)Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark BMC Public Health 12 1082-426

[7] Vignat J(2017)The economic burden of human papillomavirus-related precancers and cancers in Sweden PLoS One 12 142-128

[8] Ferlay J(2018)Activity-based costing and time-driven activity-based costing for assessing the costs of Cancer prevention, diagnosis, and treatment: a systematic review of the literature Value Health Reg Issues 17 djv086-316

[9] Bray F(2015)US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines J Natl Cancer Inst 107 2197-402

[10] Plummer M(1996)Cost of breast cancer treatment: a 4-year longitudinal study Arch Intern Med 156 417-undefined

[1] Forman D(2012)Global burden of human papillomavirus and related diseases Vaccine 30 F12-F23

[2] de Martel C(2014)Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials Lancet 383 524-532

[3] Lacey CJ(2012)Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway Br J Cancer 106 1571-71

[4] Soerjomataram I(2015)Kostnader ved masseundersøkelsen mot livmorhalskreft Sykeplein Forskning 10 62-147

[5] Lortet-Tieulent J(2014)Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys PLoS ONE 9 e89974-2201

[6] Bruni L(2012)Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark BMC Public Health 12 1082-426

[7] Vignat J(2017)The economic burden of human papillomavirus-related precancers and cancers in Sweden PLoS One 12 142-128

[8] Ferlay J(2018)Activity-based costing and time-driven activity-based costing for assessing the costs of Cancer prevention, diagnosis, and treatment: a systematic review of the literature Value Health Reg Issues 17 djv086-316

[9] Bray F(2015)US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines J Natl Cancer Inst 107 2197-402

[10] Plummer M(1996)Cost of breast cancer treatment: a 4-year longitudinal study Arch Intern Med 156 417-undefined